NASDAQ:RNXT RenovoRx (RNXT) Stock Price, News & Analysis → Truth about Trump you’ve never heard (From Porter & Company) (Ad) Free RNXT Stock Alerts $1.34 -0.06 (-4.29%) (As of 05/23/2024 ET) Add Compare Share Share Today's Range$1.34▼$1.3950-Day Range$1.14▼$1.4752-Week Range$0.53▼$3.29Volume23,969 shsAverage Volume50,493 shsMarket Capitalization$32.09 millionP/E RatioN/ADividend YieldN/APrice Target$8.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get RenovoRx alerts: Email Address RenovoRx MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside534.3% Upside$8.50 Price TargetShort InterestHealthy0.19% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.81Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.91 out of 5 starsMedical Sector592nd out of 916 stocksPharmaceutical Preparations Industry271st out of 412 stocks 3.3 Analyst's Opinion Consensus RatingRenovoRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageRenovoRx has received no research coverage in the past 90 days.Read more about RenovoRx's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.19% of the float of RenovoRx has been sold short.Short Interest Ratio / Days to CoverRenovoRx has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in RenovoRx has recently decreased by 39.85%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldRenovoRx does not currently pay a dividend.Dividend GrowthRenovoRx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RNXT. Previous Next 2.7 News and Social Media Coverage News SentimentRenovoRx has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for RenovoRx this week, compared to 1 article on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, RenovoRx insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.10% of the stock of RenovoRx is held by insiders.Percentage Held by InstitutionsOnly 3.10% of the stock of RenovoRx is held by institutions.Read more about RenovoRx's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of RenovoRx is -1.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of RenovoRx is -1.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRenovoRx has a P/B Ratio of 19.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about RenovoRx's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsWARNING about the death of the U.S. dollar…Where do you turn during times of economic uncertainty? Many elites trust storing their wealth in gold (which has historically boomed when the dollar’s value has plummeted!)Get Colonial Metals' new Precious Metals Investment Guide. About RenovoRx Stock (NASDAQ:RNXT)RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. The company was founded in 2009 and is headquartered in Los Altos, California.Read More RNXT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RNXT Stock News HeadlinesMay 21 at 9:34 AM | finance.yahoo.comPublication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx’s TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment DeliveryMay 21 at 9:00 AM | businesswire.comPublication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx's TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment DeliveryMay 14, 2024 | finance.yahoo.comRenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024May 13, 2024 | investorplace.comRNXT Stock Earnings: RenovoRx Beats EPS for Q1 2024May 2, 2024 | businesswire.comRenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024April 26, 2024 | finance.yahoo.comRenovoRx Regains Compliance with Nasdaq Stockholders’ Equity RequirementApril 20, 2024 | investing.comRenovoRx meets Nasdaq stockholders equity requirementApril 18, 2024 | fr.investing.comRenovoRx répond aux exigences du Nasdaq en matière de capitaux propresApril 18, 2024 | businesswire.comRenovoRx Regains Compliance with Nasdaq Stockholders' Equity RequirementApril 16, 2024 | businesswire.comRenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific MeetingApril 15, 2024 | finance.yahoo.comRenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026April 15, 2024 | businesswire.comRenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026April 8, 2024 | investorplace.comRNXT Stock Earnings: RenovoRx Meets EPS for Q4 2023April 8, 2024 | investorplace.comRNXT Stock Earnings: RenovoRx Meets EPS for Q4 2023April 8, 2024 | businesswire.comRenovoRx Announces $11.1 Million at Market Private PlacementApril 5, 2024 | businesswire.comRenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024March 12, 2024 | finance.yahoo.comRenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024March 10, 2024 | investing.comRenovoRx announces key leadership promotionsMarch 8, 2024 | fr.investing.comRenovoRx annonce des promotions à des postes clésMarch 8, 2024 | finance.yahoo.comRenovoRx Highlights Key Leadership PromotionsFebruary 6, 2024 | fr.investing.comRenovoRx obtient un financement pour un essai de phase III sur le cancerJanuary 29, 2024 | msn.comRenovoRx closes $6.1M private placementJanuary 29, 2024 | finance.yahoo.comRenovoRx Closes $6.1 Million Private PlacementDecember 21, 2023 | finance.yahoo.comRenovoRx Engages Oklahoma University (OU) Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct CancerDecember 19, 2023 | finance.yahoo.comRenovoRx Announces Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific MeetingSee More Headlines Receive RNXT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RenovoRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/10/2024Today5/23/2024Next Earnings (Estimated)8/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RNXT CUSIPN/A CIK1574094 Webwww.renovorx.com Phone650-284-4433Fax650-397-4433Employees8Year FoundedN/APrice Target and Rating Average Stock Price Target$8.50 High Stock Price Target$13.00 Low Stock Price Target$4.00 Potential Upside/Downside+534.3%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,230,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-2,860.14% Return on Assets-203.57% Debt Debt-to-Equity RatioN/A Current Ratio4.26 Quick Ratio4.26 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.07 per share Price / Book19.14Miscellaneous Outstanding Shares23,950,000Free Float22,251,000Market Cap$32.09 million OptionableNot Optionable Beta1.08 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Ramtin Agah M.D. (Age 57)Founder, Chairman of Board & Chief Medical Officer Comp: $332.89kMr. Shaun R. Bagai (Age 47)CEO & Director Comp: $589.38kMr. Ronald B. Kocak CPA (Age 67)CGMA, VP, Controller & Principal Accounting Officer Ms. Leesa Gentry (Age 54)Chief Clinical Officer Key CompetitorsProMIS NeurosciencesNASDAQ:PMNSpruce BiosciencesNASDAQ:SPRBSensei BiotherapeuticsNASDAQ:SNSEViracta TherapeuticsNASDAQ:VIRXJanOneNASDAQ:JANView All CompetitorsInsidersAngela NelmsBought 1,100 shares on 10/3/2023Total: $1,155.00 ($1.05/share)View All Insider Transactions RNXT Stock Analysis - Frequently Asked Questions Should I buy or sell RenovoRx stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for RenovoRx in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RNXT shares. View RNXT analyst ratings or view top-rated stocks. What is RenovoRx's stock price target for 2024? 3 brokerages have issued 1-year price objectives for RenovoRx's stock. Their RNXT share price targets range from $4.00 to $13.00. On average, they predict the company's share price to reach $8.50 in the next year. This suggests a possible upside of 534.3% from the stock's current price. View analysts price targets for RNXT or view top-rated stocks among Wall Street analysts. How have RNXT shares performed in 2024? RenovoRx's stock was trading at $2.29 on January 1st, 2024. Since then, RNXT stock has decreased by 41.5% and is now trading at $1.34. View the best growth stocks for 2024 here. When is RenovoRx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 21st 2024. View our RNXT earnings forecast. How were RenovoRx's earnings last quarter? RenovoRx, Inc. (NASDAQ:RNXT) issued its quarterly earnings results on Friday, May, 10th. The company reported ($0.07) earnings per share (EPS) for the quarter. When did RenovoRx IPO? RenovoRx (RNXT) raised $18 million in an initial public offering on Thursday, August 26th 2021. The company issued 1,800,000 shares at $9.00-$11.00 per share. Roth Capital Partners and Maxim Group LLC served as the underwriters for the IPO. How do I buy shares of RenovoRx? Shares of RNXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RNXT) was last updated on 5/23/2024 by MarketBeat.com Staff From Our Partners[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaBuy this small stock before coming AI Tidal WaveChaikin Analytics**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge AlertsThis could mean the end of the U.S dollar…Colonial MetalsElon to Transform U.S. Economy? Porter & Company41 banks launch ‘crypto dollar’Stansberry ResearchTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeThe #1 Crypto for AIWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RenovoRx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.